IP Library › Granted Patent US 12,048,741
Granted Patent B2
US 12,048,741 · App. 17/031,082 · Granted Jul 30, 2024

Recombinant host cell with heterologous nucleic acids encoding SHREK proteins

Inventors: Yuntao Wu (Manassas, VA); Deemah Dabbagh (Fairfax, VA); Sijia He (Manassas, VA); Brian Hetrick (Woodbridge, VA)
Assignee: GEORGE MASON UNIVERSITY
A61K39/12A61K38/162C12N15/86A61K2039/507A61K2039/5254
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,048,741
App. No.
17/031,082
Granted
Jul 30, 2024
Kind
B2
Abstract

Recombinant viruses include one or more SHREK proteins and are thereby rendered non-infective and can be safely used in vaccines, e.g. to treat or prevent infections and to eliminate e.g. latent virus reservoirs.

Claims (23)

1. A recombinant host cell comprising

one or more vectors comprising heterologous nucleic acid sequences encoding

one or more Surface-Hinged, Rigidly-Extended Killer (SHREK) proteins selected from the group consisting of CD43, TMEM123, CD164, Tim-1, CD34, PODXL2, CD45, CD44, Madcam1, glycam1, Cd68, CD148, CX3CL1, CD107a, CD99, and CD7, and

a viral genome selected from the group consisting of coronavirus, a lentivirus, a hepadnavirus, and an influenza virus.

2. The host cell of claim 1 , wherein the host cell is a mammalian cell.

3. The recombinant host cell of claim 1 wherein the viral genome is a lentivirus.

4. The recombinant host cell of claim 3 wherein the lentivirus is HIV-1.

5. The recombinant host cell of claim 1 wherein the viral genome is a coronavirus.

6. The recombinant host cell of claim 5 wherein the coronavirus is SARS-CoV-2.

7. The recombinant host cell of claim 1 wherein the viral genome is a hepadnavirus.

8. The recombinant host cell of claim 7 wherein the hepadnavirus is HBV.

9. A method of producing virions, comprising

I) introducing into a host cell

a nucleic acid sequence encoding at least one Surface-Hinged, Rigidly-Extended Killer (SHREK) protein, wherein the at least one SHREK protein is selected from the group consisting of CD43, TMEM123, CD164, Tim-1, CD34, PODXL2, CD45, CD44, Madcam1, glycam1, Cd68, CD148, CX3CL1, CD107a, CD99, and CD7, and

one or more nucleic acid sequences encoding a viral genome;

II) culturing the host cell in a culture medium under conditions that permit

i) over-expression of the SHREK protein from the nucleic acid sequence and over-expression of viral proteins and viral nucleic acids from the one or more nucleic acid sequences, and

ii) assembly of the viral proteins and viral nucleic acids into virions comprising the SHREK protein; and

III) recovering the virions from the culture medium.

10. The method of claim 9 wherein the host cell is a mammalian cell.

11. The method of claim 9 wherein the viral genome is selected from the group consisting of coronavirus, a lentivirus, a hepadnavirus, and an influenza virus.

12. The method of claim 11 wherein the viral genome is a lentivirus.

13. The method of claim 12 wherein the lentivirus is HIV-1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: WU, YUNTAO; DABBAGH, DEEMAH; HE, SIJIA; HETRICK, BRIAN
To: GEORGE MASON UNIVERSITY
Reel/Frame 054067/0115 →
Continuity (4)
Provisional Application 63061683 · Aug 5, 2020
Provisional Application 63008054 · Apr 10, 2020
Provisional Application 62906890 · Sep 27, 2019
Related Publication 20210093709A1 · Apr 1, 2021